HTGC•benzinga•
Phathom Pharma Reports Revenue-Interest Financing For Up To $260M In Non-Dilutive Capital, Including Upfront Payment Of $100M In Cash, Added $160M In Payment Upon FDA Approval Of Vonoprazan
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 4, 2022 by benzinga